7 north test - Company finances
|
EUR
|
2022
From: 2022-03-21
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 33,722 | 35,418 | 5,665 | 8,680 |
| Profit before tax | 20,842 | 27,573 | - | 5,703 |
| Net profit | 19,800 | 26,194 | -525 | 5,361 |
| Equity | 19,900 | 47,473 | - | 52,834 |
| Liabilities | 1,410 | -4,146 | 0 | 2,393 |
| Non-current assets | 0 | 0 | 0 | 0 |
| Current assets | 21,310 | 43,327 | 0 | 55,227 |
| Total assets | 21,310 | 43,327 | 0 | 55,227 |
|
Taxes paid
|
||||
| STI taxes | - | 5 | - | 1,042 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +5.0% | -84.0% | +53.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 92.9% | 60.5% | - | 9.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 99.5% | 55.2% | - | 10.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 58.7% | 74.0% | -9.3% | 61.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 61.8% | 77.9% | - | 65.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | - | - | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
7 north test - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-01-02 | 2025-01-31 | 387.00 |
| 2024-12-03 | 2024-12-31 | 258.00 |
| 2024-11-04 | 2024-12-02 | 129.00 |
| 2024-10-11 | 2024-10-31 | 77.67 |
| 2024-10-09 | 2024-10-10 | 110.78 |
| 2024-10-01 | 2024-10-08 | 258.00 |
| 2024-09-03 | 2024-09-30 | 129.00 |
| 2024-08-01 | 2024-09-02 | 64.50 |
| 2024-07-22 | 2024-07-31 | 56.84 |
| 2024-07-19 | 2024-07-21 | 124.95 |
| 2024-07-17 | 2024-07-18 | 158.06 |
| 2024-07-15 | 2024-07-16 | 191.17 |
| 2024-07-12 | 2024-07-14 | 224.28 |
| 2024-07-02 | 2024-07-11 | 258.00 |
| 2024-06-03 | 2024-07-01 | 193.50 |
| 2024-05-02 | 2024-06-02 | 129.00 |
| 2024-04-03 | 2024-05-01 | 64.50 |
| 2024-03-01 | 2024-03-31 | 19.99 |
| 2022-08-05 | 2022-10-31 | 101.90 |
| 2022-08-02 | 2022-08-04 | 152.85 |
| 2022-07-01 | 2022-08-01 | 101.90 |
| 2022-05-03 | 2022-06-30 | 50.95 |
| 2022-04-01 | 2022-04-30 | 14.79 |
7 north test - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company 7 north test is: 1 €
| From | To | Overdue, € |
|---|---|---|
| 2026-07-01 | 2026-09-02 | 0.63 |
| 2025-09-30 | 2025-09-30 | 125.61 |
| 2025-09-09 | 2025-09-17 | 1042.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
7 north test, MB (code 306047668) is a Small partnership engaged in other human health activities n.e.c. In 2025, the company generated revenue of €8.7K and net profit of €5.4K, with a net profit margin of 61.8%. Results improved from 2024, when revenue was €5.7K and the company posted a net loss of €525, but they remained well below 2023, when revenue reached €35.4K and net profit amounted to €26.2K. Over the two-year period from 2023 to 2025, revenue declined materially overall, although 2025 revenue was 53.2% higher year on year. The 2025 balance sheet showed total assets of €55.2K, equity of €52.8K and liabilities of €2.4K, giving an equity ratio of 95.7% and debt-to-equity of 0.05. Profitability remained positive in 2025, with ROE of 10.2% and ROA of 9.7%. Asset turnover was 0.16x, indicating that revenue remained low relative to the asset base.